Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04985604 · ClinicalTrials.gov registry record · Phase 2
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
A Phase 2 study, sponsored by Day One Biopharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT04985604 is a Phase 2 study that was terminated before completion, run by Day One Biopharmaceuticals. The registered enrollment target is 23 participants.
The verdict
NCT04985604, a Phase 2 study, was terminated before completion, sponsored by Day One Biopharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions or amplification.
Interventions
- DRUG Tovorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2024-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04985604
The ClinicalTrials.gov registry entry for NCT04985604 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Day One Biopharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tovorafenib is the first listed.
NCT04985604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04985604 about?
NCT04985604 is a clinical study titled "Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors". This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions or amplification.
What is the current status of trial NCT04985604?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2021-07-15. Estimated completion is 2024-07-08.
What interventions are being tested in trial NCT04985604?
The interventions under investigation include: Tovorafenib (DRUG).
Who is sponsoring clinical trial NCT04985604?
This trial is sponsored by Day One Biopharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.